A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC

A Translational Study of Tumor Antigen-pulsed Dendritic Cell Vaccine for Esophageal Squamous Cell Carcinoma

The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-pulsed DC vaccine( OCDC and NeoDC) for postoperative adjuvant treatment of ESCC

Inclusion Criteria:

• Pathologically confirmed diagnosis of esophageal squamous cell carcinoma
• no preoperative adjuvant therapy
• Karnofsky performance status 0-2;
• The postoperative pathological stage is pT2-4 and / or N + M0 according to AJCC 8th
• Function of the main organs is normal;
• Edition Patient's written informed consent

Exclusion Criteria:

• Tumor emergencies;
• Abnormal coagulation function;
• Contagious diseases, such as HIV, HBV, HCV infection;
• Mental disorders;
• Concomitant tumors;
• Immunological co-morbidities